IP Library › Granted Patent US 9,005,601
Granted Patent B2
US 9,005,601 · App. 13/810,549 · Granted Apr 14, 2015

Methods and compositions including spore-forming bacteria for increasing the health of animals

Inventors: Billy Hargis (Fayetteville, AR); Ross Wolfenden (Pea Ridge, AR); Neil R. Pumford (Bentonville, AR); Marion Morgan (Springdale, AR); Anita Menconi (Fayetteville, AR); Guillermo Tellez (Fayetteville, AR); Amanda Wolfenden (Pea Ridge, AR); Srichaitanya Shivaramaiah (Kitchener, CA)
Assignee: The Board of Trustees of the University of Arkansas
C12N1/20A23K1/002A23K1/009A23K1/1826A23L1/3014A61K35/742
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,601
App. No.
13/810,549
Granted
Apr 14, 2015
Kind
B2
Abstract

Methods, compositions and bacterial isolates for improving the gastrointestinal health of animals and in particular of poultry are provided herein. The methods include administering an endospore-forming bacteria to an animal. The bacteria are selected for the ability to reduce the growth and presence of bacterial pathogens, such as Salmonella, Clostridium , and Campylobacter , in the gastrointestinal tract of the animal. The bacteria are also selected for the ability to improve at least one production parameter in the animal.

Claims (20)

1. A probiotic formulation comprising a bacterial isolate selected from the group of Bacillus subtilis AM0904 (NRRL Deposit Number B-50914), Bacillus subtilis AM0911 (NRRL Deposit Number B-50915), Bacillus subtilis NP122 (NRRL Deposit Number B-50910), Bacillus subtilis NP119B (NRRL Deposit Number B-50909), B. licheniformis B1 (NRRL Deposit Number B-50907), B. subtilis B2 (Deposit Number B-50908), B. licheniformis RW25 (NRRL Deposit Number B-50911), B. licheniformis RW32 (NRRL Deposit Number B-50912), and B. licheniformis RW41 (NRRL Deposit Number B-50913), wherein the formulation comprises at least one Bacillus subtilis isolate and at least one Bacillus licheniformis isolate, or at least two Bacillus subtilis isolates.

2. The probiotic formulation of claim 1 , wherein the probiotic formulation is capable of improving gastrointestinal tract health in poultry.

3. The probiotic formulation of claim 2 , wherein improving the gastrointestinal tract health comprises at least one of reducing potential bacterial food-borne pathogens of humans from the gastrointestinal tract of commercial poultry, reducing at least one of Salmonella, Campylobacter or Clostridium perfringens in the gastrointestinal tract of poultry, or increasing the daily weight gain of the poultry.

4. The probiotic formulation of claim 1 , wherein the ratio of one Bacillus subtilis isolate and one Bacillus licheniformis isolate, or two Bacillus subtilis isolates is between 0.5:1 and 3:1 colony forming units (cfu).

5. The probiotic formulation of claim 1 , wherein the Bacillus subtilis isolates comprise NP122, AM0904 or B2.

6. The probiotic formulation of claim 5 , wherein the Bacillus subtilis isolates NP122, B2 and AM0904 are present in a ratio of about 5:5:1 colony forming units (cfu).

7. The probiotic formulation of claim 1 , wherein the formulation is configured to be administered via an agricultural animal feed substrate.

8. An animal feed comprising the probiotic formulation of claim 1 , wherein the feed comprises between 10 4 and 10 9 spores/gram finished feed.

9. The probiotic formulation of claim 1 , wherein the bacterial isolates are capable of reducing the severity of necrotic enteritis in poultry, and wherein the bacterial isolates are not capable of hemolysis and are considered as Generally Recognized As Safe by the United States Food and Drug Administration.

10. A method for improving gastrointestinal tract health in animals comprising:

administering a probiotic formulation to an animal, comprising a bacterial isolate selected from the group of Bacillus subtilis AM0904 (NRRL Deposit Number B-50914), Bacillus subtilis AM0911 (NRRL Deposit Number B-50915), Bacillus subtilis NP122 (NRRL Deposit Number B-50910), Bacillus subtilis NP119B (NRRL Deposit Number B-50909), B. licheniformis B1 (NRRL Deposit Number B-50907), B. subtilis B2 (Deposit Number B-50908), B. licheniformis RW25 (NRRL Deposit Number B-50911), B. licheniformis RW32 (NRRL Deposit Number B-50912), and B. licheniformis RW41 (NRRL Deposit Number B-50913), wherein the formulation comprises at least one Bacillus subtilis isolate and at least one Bacillus licheniformis isolate, or at least two Bacillus subtilis isolates, wherein the bacterial isolates are capable of reducing growth of Salmonella enteritidis, Campylobacter jejuni and Clostridium perfringens in vitro and are capable of reducing the growth of Salmonella typhimurium in the gastrointestinal tract of the animal, and wherein the bacterial isolates are capable of persisting in the gastrointestinal tract of poultry for over six hours.

11. The method of claim 10 , wherein the probiotic formulation is administered as an endospore comprised within a dry pelleted animal feed.

12. The method of claim 10 , wherein the bacterial isolates are capable of reducing the severity of necrotic enteritis in poultry, and wherein the bacterial isolates are not capable of hemolysis and are considered as Generally Recognized As Safe by the United States Food and Drug Administration.

13. The method of claim 10 , wherein the probiotic formulation is administered via the animal feed.

14. The method of claim 10 , wherein the bacterial isolates are capable of surviving animal feed processing.

15. The method of claim 1 , wherein the animals are poultry.

16. The method of claim 10 , wherein the probiotic formulation improves at least one production parameter in the animal, wherein the production parameter is selected from increasing the daily weight gain of the animal, or decreasing morbidity or mortality of the animal from bacterial pathogens.

17. A method for improving gastrointestinal tract health in an animal comprising: orally administering a probiotic formulation comprising a bacterial isolate selected from the group of Bacillus subtilis AM0904 (NRRL Deposit Number B-50914), Bacillus subtilis AM0911 (NRRL Deposit Number B-50915), Bacillus subtilis NP122 (NRRL Deposit Number B-50910), Bacillus subtilis NP119B (NRRL Deposit Number B-50909), B. licheniformis B1 (NRRL Deposit Number B-50907), B. subtilis B2 (Deposit Number B-50908), B. licheniformis RW25 (NRRL Deposit Number B-50911), B. licheniformis RW32 (NRRL Deposit Number B-50912), and B. licheniformis RW41 (NRRL Deposit Number B-50913), wherein the formulation comprises at least one Bacillus subtilis isolate and at least one Bacillus licheniformis isolate, or at least two Bacillus subtilis isolates to the animal.

18. The method of claim 17 , wherein oral administration includes delivery via feed, water, oral gavage, or aerosol spray.

19. The method of claim 17 , wherein the animal is poultry.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2013
From: HARGIS, BILLY; WOLFENDEN, ROSS; PUMFORD, NEIL R.; MENCONI, ANITA; TELLEZ, GUILLERMO; MORGAN, MARION; WOLFENDEN, AMANDA; SHIRVARAMAIAH, SRICHAITANYA
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 030225/0134 →
Continuity (2)
Provisional Application 61365188 · Jul 16, 2010
Related Publication 20130136695A1 · May 30, 2013